Other trauma applications

Preclinical studies across multiple injury models suggest that VANADIS® may have therapeutic potential in conditions driven by ischemia–reperfusion and inflammation, including stroke, surgical injury, and multiple organ dysfunction syndrome (MODS).

Acute kidney injury (AKI)

AKI is a sudden, inflammation-driven loss of kidney function. It affects about 2 million people each year across Europe, the USA, and Japan, and approximately 700,000 of these patients die. AKI occurs in roughly 4% of all hospital admissions and up to 40% of intensive-care (often trauma-related) admissions. Depending on cause and severity, mortality ranges from 10% to 70%.

In intensive care, the most common pathway to AKI is acute tubular necrosis due to renal ischemia (e.g., hypotension, sepsis), toxic injury (e.g., certain drugs or contrast dye), or a combination of both.

In preclinical models, treatment with VANADIS® significantly reduced renal reperfusion damage, supporting further evaluation of VANADIS® as a potential therapy for AKI.